Resolutions from the Annual General Meeting of Novo Nordisk A/S - Seite 2

The meeting was held as a hybrid meeting enabling shareholders to participate either in person or virtually. The shareholders had been encouraged to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting.

Composition of the Board of Directors and its committees
After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.

The Board of Directors, including its committees, is now composed as follows:

• Helge Lund (chair of the Board and chair of the People and Governance Committee)
• Henrik Poulsen (vice chair of the Board, chair of the Remuneration Committee and member of the Audit Committee)
• Elisabeth Dahl Christensen (employee representative and member of the Remuneration Committee)
• Laurence Debroux (chair of the Audit Committee and member of the Remuneration Committee)
• Andreas Fibig (member of the Research & Development Committee)
• Sylvie Grégoire (member of the Audit Committee, the People and Governance Committee and the Research & Development Committee)
• Liselotte Hyveled (employee representative and member of the Research & Development Committee)
• Mette Bøjer Jensen (employee representative and member of the Audit Committee)
• Kasim Kutay (member of the People and Governance Committee and the Research & Development Committee)
• Christina Law (member of the Audit Committee)
• Martin Mackay (chair of the Research & Development Committee and member of the Remuneration Committee)
• Thomas Rantzau (employee representative and member of the People and Governance Committee)

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.